Clinical and molecular characteristics at diagnosis according to BAALC expression in B-precursor ALL
| Characteristic . | BAALC T1 (n = 123) . | BAALC T2 (n = 123) . | BAALC T3 (n = 122) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 32 (15-64) | 36 (15-65) | 42 (18-64) | < .001 |
| Male sex, percentage | 54 | 57 | 49 | .51 |
| WBC, ×109/L (n = 342) | ||||
| Median (range) | 10 (0.4-317) | 15 (0.8-472) | 20 (0.5-594) | .008 |
| More than 30 × 109/L, no. (%) | 34 (29) | 43 (37) | 46 (43) | .09 |
| CNS involvement, no. /total (%) (n = 272) | 4/96 (4) | 6/96 (6) | 3/80 (4) | .77 |
| Molecular genetics | ||||
| BCR-ABL, no. (%) | < .001 | |||
| Positive | 29 (24) | 41 (33) | 70 (57) | |
| Negative | 94 (76) | 82 (67) | 52 (43) | |
| MLL-AF4, no. (%) | < .001 | |||
| Positive | 0 (0) | 14 (11) | 11 (9) | |
| Negative | 123 (100) | 109 (89) | 111 (91) | |
| CD34 positivity, no. (%) | 79 (64) | 103 (84) | 95 (78) | .001 |
| CD20 positivity, no. (%) | 43 (35) | 49 (40) | 36 (30) | .23 |
| Myeloid markers, no. (%)* | 50 (41) | 49 (40) | 58 (48) | .42 |
| Immunophenotypic subtype, no. (%) | .10† | |||
| Common ALL | 77 (63) | 81 (66) | 89 (73) | |
| Pre-B ALL | 37 (30) | 25 (20) | 23 (19) | |
| Pro-B ALL | 9 (7) | 17 (14) | 10 (8) |
| Characteristic . | BAALC T1 (n = 123) . | BAALC T2 (n = 123) . | BAALC T3 (n = 122) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 32 (15-64) | 36 (15-65) | 42 (18-64) | < .001 |
| Male sex, percentage | 54 | 57 | 49 | .51 |
| WBC, ×109/L (n = 342) | ||||
| Median (range) | 10 (0.4-317) | 15 (0.8-472) | 20 (0.5-594) | .008 |
| More than 30 × 109/L, no. (%) | 34 (29) | 43 (37) | 46 (43) | .09 |
| CNS involvement, no. /total (%) (n = 272) | 4/96 (4) | 6/96 (6) | 3/80 (4) | .77 |
| Molecular genetics | ||||
| BCR-ABL, no. (%) | < .001 | |||
| Positive | 29 (24) | 41 (33) | 70 (57) | |
| Negative | 94 (76) | 82 (67) | 52 (43) | |
| MLL-AF4, no. (%) | < .001 | |||
| Positive | 0 (0) | 14 (11) | 11 (9) | |
| Negative | 123 (100) | 109 (89) | 111 (91) | |
| CD34 positivity, no. (%) | 79 (64) | 103 (84) | 95 (78) | .001 |
| CD20 positivity, no. (%) | 43 (35) | 49 (40) | 36 (30) | .23 |
| Myeloid markers, no. (%)* | 50 (41) | 49 (40) | 58 (48) | .42 |
| Immunophenotypic subtype, no. (%) | .10† | |||
| Common ALL | 77 (63) | 81 (66) | 89 (73) | |
| Pre-B ALL | 37 (30) | 25 (20) | 23 (19) | |
| Pro-B ALL | 9 (7) | 17 (14) | 10 (8) |